1-氨基-1-环己烷羧酸甲酯盐酸盐 | 37993-32-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-氨基-1-环己烷羧酸甲酯盐酸盐
• 英文名称: 1-amino-cyclohexanecarboxylic acid methyl ester hydrochloride
• 英文别名: methyl 1-aminocyclohexanecarboxylate hydrochloride；methyl 1-aminocyclohexane-1-carboxylate hydrochloride；(1-Methoxycarbonylcyclohexyl)azanium;chloride；(1-methoxycarbonylcyclohexyl)azanium;chloride
• CAS: 37993-32-1
• 化学式: C₈H₁₅NO₂*ClH
• mdl: MFCD09264353
• 分子量: 193.674
• InChiKey: MTPXRXOMKRLUMU-UHFFFAOYSA-N

物化性质

• 熔点：
  210-212 °C(Solv: methanol (67-56-1); ethyl ether (60-29-7))

计算性质

• 辛醇/水分配系数(LogP)：
  1.03
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P301+P310,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下，应保存于惰性气体中。

反应信息

• 作为反应物：
  描述：

  1-氨基-1-环己烷羧酸甲酯盐酸盐 在 sodium hydroxide 、 TEA 、 氯甲酸异丁酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 Boc-Tyr-Ac6c-Phe-OMe
  参考文献：
  名称：

  Design and Synthesis of 1-Aminocycloalkane-1-carboxylic Acid-Substituted Deltorphin Analogues:  Unique δ and μ Opioid Activity in Modified Peptides

  摘要：

  Deltorphin analogues were substituted by a series of achiral C-alpha,C-alpha-dialkyl cyclic alpha-amino acids (1-aminocycloalkane-1-carbaxylic acids, Ac(x)c, where (x) = a hexane, pentane, or propane cycloalkane ring) in position 2, 3, 4, or 2 and 3 in deltorphin C, and in position 2 in [Ac(6)(c)2,- des-Phe(3)]deltorphin C hexapeptide. Receptor assays indicated that even though Ac(6)c(2) and Ac(6)c(3) exhibited a diminished K-i delta by ca. 20-fold (2.5-3.3 nM) relative to deltorphin C (K-i delta = 0.15 nM), selectivity was marginally elevated (K-i mu/K-i delta = 1250) or enhanced by about 70%, and both peptides fitted stringent iterative calculations for a two-site binding model (eta = 0.625 and 0.766, respectively, P < 0.0001). The disubstituted [Ac(6)c(2,3)]- or [Ac(6)c(2),des-Phe(3)]deltorphin analogues yielded peptides with decreased K-i delta, such that the latter peptide was essentially inactive. The presence of Ac(5)c or Ac(3)c in place of Phe(3) further diminished K-i delta (15.4 to 19.0 nM), yet delta selectivity only fell about one-half(K-i mu/K-i delta = 440 and 535, respectively), and only the former peptide fitted a two-site binding model (eta = 0.799). The replacement of Asp(4) by Ac(6)c, Ac5c, or Ac(3)c produced essentially nonselective analogues through the acquisition of high mu affinities (2.5, 0.58, and 0.27 nM, respectively) while maintaining high delta affinities (K-i delta = 0.045-0;054 nM) which were about 3 fold greater than that of deltorphin C. Using pharmacological assays in vitro (mouse vas deferens and guinea pig ileum), position 3-substituted analogues all indicated substantial losses in bioactivity, whereas substitution by 1-aminocycloalkanes at the fourth position retained high delta activity. In fact, the bioactivity of [Ac(3)c(4)]deltorphin C indicated a peptide with relatively weak delta selectivity, which was comparable to the observations with the receptor binding data. In summary, the data confirmed that (i) delta selectivity occurs in the absence of D-chirality at position 2, (ii) the aromaticity of Phe(3) is replaceable by an achiral residue with a hydrophobic ring-saturated side chain, and (iii) the acquisition of dual high-affinity analogues occurs through the elimination of the anionic function at position 4 and replacement by an amino acid with a hydrophobic side chain.

  DOI：

  10.1021/jm950490j
• 作为产物：
  描述：

  methyl 1-((t-butoxycarbonyl)amino)cyclohexane-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-氨基-1-环己烷羧酸甲酯盐酸盐
  参考文献：
  名称：

  Toward the Back-Up of Boceprevir (SCH 503034): Discovery of New Extended P₄-Capped Ketoamide Inhibitors of Hepatitis C Virus NS3 Serine Protease with Improved Potency and Pharmacokinetic Profiles

  摘要：

  Hepatitis C is the most prevalent liver disease. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically an estimated 300 million people worldwide. Results of Phase I clinical studies with our first generation HCV inhibitor Boceprevir, SCH 503034 (1), presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) were encouraging, and thus, additional human clinical studies are underway. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P-4 pocket and optimization of the P-1' capping led to the discovery of new ketoamide inhibitors of the HCV NS3 serine protease with improved in vitro potency. In addition to being potent inhibitors of HCV subgenomic RNA replication, some of the new P-4-capped inhibitors were also found to have improved PK profile.

  DOI：

  10.1021/jm801632a
• 作为试剂：
  描述：

  1-氨基-1-环己基甲酸 、 氯化亚砜 、 乙醚 在 盐酸 、 1-氨基-1-环己烷羧酸甲酯盐酸盐 作用下， 以 甲醇 为溶剂， 反应 6.03h， 生成 1-氨基-1-环己烷羧酸甲酯盐酸盐
  参考文献：
  名称：

  5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists

  摘要：

  本发明涉及通式化合物及其药物组合物。本发明还涉及它们作为尿激肽II受体拮抗剂的治疗用途，例如用于治疗心脏、冠状动脉和中枢神经系统疾病。在特定实施例中，本发明涉及5,6-双芳基-2-吡啶羧酰胺的制备及其作为尿激肽II受体拮抗剂的治疗用途。

  公开号：

  US08466292B2

文献信息

• Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same
  申请人：Kobayashi Nobuo

  公开号：US20090137799A1

  公开（公告）日：2009-05-28

  Cycloalkylcarbonylamino acid ester derivatives, which are raw material intermediates for a novel cycloalkane carboxamide derivative having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkylcarbonylamino acid ester derivative represented by formula (I), or a pharmaceutically acceptable salt thereof: (wherein, R 1 and R 2 represent alkyl groups, alkenyl groups, alkynyl groups, aromatic hydrocarbon groups, heterocyclic groups, etc., R 8 represents an alkyl group having 1 to 6 carbon atoms, and ring A represents a cyclic alkylidene group having 5, 6 or 7 carbon atoms).

  环烷基羰基氨基酸酯衍生物是一种新型环烷烃羧酰胺衍生物的原料中间体，具有选择性抑制卡特普辛K的作用，提供其生产工艺。 表示为式（I）的环烷基羰基氨基酸酯衍生物，或其药学上可接受的盐： （其中，R1和R2代表烷基、烯基、炔基、芳香烃基、杂环基等，R8代表具有1至6个碳原子的烷基，环A代表具有5、6或7个碳原子的环烷基亚基）。
• 特胺酸衍生物及其制备方法与应用
  申请人：安徽农业大学

  公开号：CN113402436A

  公开（公告）日：2021-09-17

  本发明提供一种特胺酸衍生物及其制备方法与应用。所述特胺酸衍生物的结构如下：其中，R选自甲基、甲氧基等；R1选自C1‑C4脂肪烃基、苯甲基等；R2选自氢、含有苯环的羰基、含有脂肪烃的羰基或C1‑C4脂肪烃基等。本发明提供的特胺酸衍生物与已报道的化合物相比，通过用天然氨基酸甲酯对先导化合物进行修饰和结构优化，筛选出的化合物对农作物的生长基本没有影响，能有效杀死多种害虫，而且残留的量很少且容易去除残留的化合物，对环境污染小，结构新颖，原料廉价易得，合成方法简单高效，社会效益和经济效益显著，适合工业化生产。
• 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS
  申请人：Altenburger Jean-Michel

  公开号：US20110009426A1

  公开（公告）日：2011-01-13

  The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists.

  这项发明涉及5,6-双芳基-2-吡啶甲酰胺，以及它们的制备和作为尿苷II受体拮抗剂的治疗用途。
• SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES
  申请人：Bouey Edith

  公开号：US20100004159A1

  公开（公告）日：2010-01-07

  The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

  本发明涉及多取代咪唑酮衍生物，包括它们的药物组合物以及在人类和动物健康领域中的治疗用途。本发明还涉及一种制备这些衍生物的方法。
• Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same
  申请人：Kobayashi Nobuo

  公开号：US20090111983A1

  公开（公告）日：2009-04-30

  Cycloalkylcarbonylamino acid derivatives, which are raw material intermediates of a novel cycloalkane carboxamide derivative that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkylcarbonylamino acid derivative represented by the following general formula (I), or a pharmaceutically acceptable salt thereof: (wherein, R 1 and R 2 represent alkyl groups, alkenyl groups, alkynyl groups, aromatic hydrocarbon groups, heterocyclic groups or the like, and ring A represents a cyclic alkylidene group having 5, 6 or 7 carbon atoms).

  环烷基羰基氨基酸衍生物是一种新型环烷基羧酰胺衍生物的原料中间体，该衍生物选择性抑制卡特普辛K，并提供其生产工艺。 以下是由下述通用式（I）表示的环烷基羰基氨基酸衍生物，或其药用可接受盐： （其中，R1和R2代表烷基、烯基、炔基、芳香烃基、杂环基或类似基团，环A代表具有5、6或7个碳原子的环烷基亚基）。